C
Circulate
FDA-cleared Therapeutic Plasma Exchange (TPE) for anti-aging, delivered through a growing network of independent medical clinics in the US
About Circulate
Circulate Health is focused on the anti-aging and wellness market by providing Therapeutic Plasma Exchange (TPE) treatments. The company's core offering is built upon proprietary, FDA-cleared apheresis technology, which is supported by two decades of scientific research and clinical trials.
Read full description
The business operates on a partnership model, expanding its services through a network of independent medical practices and clinics. Currently, TPE by Circulate is available in over 21 clinics across the United States, with a clear strategy for continued growth. This model allows the company to scale its reach by equipping partner clinics to deliver the treatments.
Circulate targets two primary client segments: patients seeking treatments to improve their quality of life and healthy lifespan, and medical clinics or doctor's offices looking to offer these services. The company's revenue is likely generated through the provision of its TPE technology and services to its partner clinics, which in turn serve the end patients. Clinical services are delivered by these independent practices, with Circulate providing the foundational technology and scientific backing.
At a glance
- Status
- Acquired
- Founded
- 2021
- Headquarters
- Seattle, United States
- Employees
- 23
- Open positions
- 1
- Dealroom signal
- 87.5/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Degenerative Diseases, Chronic Disease, Longevity, Preventive Care, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Circulate.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Aug 2026 | $0 | — | Viome | ↗ |
| EARLY VC✓Equity / VC | Dec 2025 | $0 | — | Scrum Ventures | ↗ |
Growth signals
Latest recorded traffic for Circulate is 2K monthly website visits, down 4.8% over the last three months. Circulate's team grew 64.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A1 investor entered at this stage
Scrum Ventures
Other known investors2 additional known investors
Viome
Seaside Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Circulate on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Circulate’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.